Please assess the completion status of the following clinical trial:

Trial Title: Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:Patients eligible for inclusion in this study have to fulfill all of the following criteria:~* Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)~* Rheumatoid factor and anti-CCP antibodies negative at screening~* Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or documented history of plaque psoriasis~* Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization with inadequate control of symptoms or at least one dose if stopped due to intolerance to NSAIDs~* Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or equivalent for at least 2 weeks before randomization and should remain on a stable dose up to Week 24~* Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the dose is stable for at least 4 weeks before randomization and should remain on a stable dose up to Week 52.~Exclusion Criteria:Patients fulfilling any of the following criteria are not eligible for inclusion in this study:~* Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician~* Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)~* Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor~* Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, UV therapy) at randomization. The following wash out periods need to be observed:~* Oral or topical retinoids 4 weeks~* Photochemotherapy (e.g. PUVA) 4 weeks~* Phototherapy (UVA or UVB) 2 weeks~* Topical skin treatments (except in face, scalp and genital area during screening, only corticosteroids with mild to moderate potency) 2 weeks~* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα, investigational or approved~* Previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (AIN457) 75 mg s.c. (Type: EXPERIMENTAL): Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
- Secukinumab (AIN457) 150 mg s.c. (Type: EXPERIMENTAL): Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
- Secukinumab (AIN457) 300 mg s.c. (Type: EXPERIMENTAL): Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
- Placebo s.c. (Type: PLACEBO_COMPARATOR): Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4. Non-responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 16. Responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).